Comprehensive Medical Weight Loss Denver
Retatrutide’s 28% Weight Loss Is Eye-Opening. But Is More Always Better? Eli Lilly dropped a bombshell earlier this month: their next-generation obesity drug retatrutide helped patients lose up to 28% of their body weight over 80 weeks in a Phase…
GLP-1 Medications Reduce Cancer Spread You already know GLP-1 medications help with weight loss. You might have heard they reduce heart attack and stroke risk. Here’s one you probably haven’t seen in the headlines yet: GLP-1s may also help prevent…
For years, the headline around obesity in America has been relentless growth. More people, higher BMI, more disease. The trajectory looked inevitable — up and to the right, year after year. That may finally be changing. New data from EPIC…
CVS just flipped the script on GLP-1 coverage — and if you’ve been stuck paying out of pocket because your plan dropped Zepbound, this matters. What’s changing: CVS Caremark, one of the nation’s largest pharmacy benefit managers, will restore coverage…
New research confirms what many of us in obesity medicine have suspected for years — GLP-1 drugs do more than help people lose weight. They protect the heart. — A massive review of more than 90,000 participants across 11 major…
Eli Lilly’s triple-action GLP-1 drug delivered striking results in the Phase III TRIUMPH-4 trial — and the knee pain data might be the most remarkable part. — If you’ve been watching the GLP-1 space, retatrutide isn’t news. But the Phase…
If you’re on a GLP-1 medication and have noticed more hair in the shower drain, you’re not imagining it. A new meta-analysis published in Science Progress (Gupta et al., PMID 41998799) confirms what many patients and clinicians have already suspected:…
📌 CNC’s Complete Medicare Guide (Updated July 1, 2026) For the full, up-to-date reference on the Medicare GLP-1 Bridge program — including who qualifies, what it costs, the CNC prior authorization process, and how to start — see our Medicare…
Most people on a GLP-1 medication hit a wall around 12-16 weeks. The scale stops moving. The dose feels like it is not doing anything anymore. Patients often feel like they have failed — but they have not. They have…
The newest GLP-1 medication just landed in pharmacies: oral semaglutide. Novo Nordisk launched it in January 2026 after FDA approval based on the OASIS 4 trial, which showed 13.6% average weight loss over 64 weeks. That’s solid. But the real…
